Xilio Therapeutics, Inc.’s Post

We recently launched our annual North America Spotlight #Report, which celebrates #milestones, #collaboration and #innovation with Johnson & Johnson across the North America region.   Of note, we are excited to have marked the 10-year anniversary of our California Innovation Center, as well as the 50-year anniversary of JJDC. We will continue this momentum and identify the most promising early-stage companies with which we can partner to ensure we are improving healthcare for patients everywhere.    Ushering in 2024, we want to especially thank our partners and collaborators alike who have continued to raise the bar in innovation, bringing us closer to solving tomorrow’s challenges in healthcare today.    For the full report: https://bit.ly/3tJpg5B   @Serotiny, @Rondo Therapeutics, @Arialys Therapeutics, @Contineum Therapeutics   #JNJInnovation #NA #lifesciences

In the fast-paced world of #ADCs (antibody-drug conjugates), where multi-billion dollar deals are the norm, what comes next? Our team (Patrick Flynn, Ph.D., Smruthi Suryaprakash, Dan Grossman, Val Panier, John Wu) has published a paper in #NRDD (Nature Review Drug Discovery) that examines the current ADC pipeline, categorizes technological innovations being explored, and assesses their potential in addressing current challenges and expanding the utility of ADCs. Check out the link below to read our insights and don't hesitate to reach out if you have any questions! https://lnkd.in/dN3yhYTs

In the fast-paced world of #ADCs (antibody-drug conjugates), where multi-billion dollar deals are the norm, what comes next? Our team (Patrick Flynn, Ph.D., Smruthi Suryaprakash, Dan Grossman, Val Panier, John Wu) has published a paper in #NRDD (Nature Review Drug Discovery) that examines the current ADC pipeline, categorizes technological innovations being explored, and assesses their potential in addressing current challenges and expanding the utility of ADCs. Check out the link below to read our insights and don't hesitate to reach out if you have any questions!

On the new episode of Carolina Pharmacy's Unscripted, Dean Kashuba spoke with Jimmy Rosen, the CEO of Rapidly Emerging Antiviral Drug Development Initiative (READDI)! They discuss the necessity of preparing for pandemics ahead of time, the work being done in antiviral drug discovery, and about how one’s career path is not always straight-forward. Watch below:

Today marks a significant milestone in our mission to create an accessible and diverse clinical trial ecosystem. EQBMED proudly welcomes Amgen and Merck as our inaugural sponsors. Amgen and Merck will co-design and pilot strategies—such as enhancing infrastructure, increasing trial capacity, and providing support to overcome barriers like travel and transportation—to foster closer engagement with local EQBMED trial sites and communities. This collaboration is key to improving medical research by bringing local trial sites, communities, and sponsors together as partners. https://lnkd.in/er4uYQEN

#ALS is a devastating disease that steals the ability to move, speak, and breathe, with a life expectancy of just 2-5 years after diagnosis. The Accelerating Medicines Partnership (AMP®) in ALS aims to be a game-changer for both ALS treatment development and diagnostic tools.  Click here to watch the full video and learn more about this initiative. fnih.org/ampals The National Institutes of Health's National Institute of Neurological Disorders and Stroke (NINDS), FDA, AbbVie, The ALS Association, ALS TDI, ALS United Mid-Atlantic, Answer ALS, The Association for Frontotemporal Degeneration (AFTD), Biogen, Critical Path Institute (C-Path), EMD Serono, Inc., GSK, Eli Lilly and Company, Mitsubishi Tanabe Pharma America, QurAlis, and Target ALS, the FNIH announces the launch of the Accelerating Medicines #BridgestoBreakthroughs #MND #MotorNeuronDisease #AmyotrophicLateralSclerosis #AMPALS

Thryv Therapeutics Inc. will be hosting their very first “Ask Thryv Live” on Tuesday, May 7th from 12:00 p.m. to 1:00 p.m. ET. First Half: Updates & Insights Wave I Studies Update: Get insights into the progress of the Wave Studies. Advancements in Atrial Fibrillation Research: Plan for the clinical program. Series B Financing Status: An update on the second round of financing which will help move forward many exciting projects. Exploring New Frontiers: Discover the innovative research into SGK1 inhibition across various indications. Second Half: Interactive Q&A Pre-submit Questions: Email your questions in advance to admin@thryvtrx.com. Ask Live: Participate actively during the webinar by submitting anonymous questions in real-time. Note: this webinar will be recorded for internal purposes but will NOT be available to watch afterwards. Please register to view the webinar and learn more about the amazing work Thryv are doing! Give a like, share and register ❤️ https://lnkd.in/e-A-cznS

So what's the common thread between successful biotech CEOs ? In preparing for this panel I thought doing 1-1 calls ahead of time would be a cool way to get to know a set of accomplished CEOs from the New England biotech community. The odds of getting everyone on one Teams call seemed pretty low right ? Well, let me say these calls have been an absolute highlight of the past month for me. The most important takeaway observation (if you can't make it to COG New England next week): The passion these CEOs have for the underlying patient challenges is what gets them moving each day. The fundraising and clinical data journey isn't easy. These CEOs press forward through that difficult journey because they understand they have an opportunity to help bring cures and treatments to the people that need them.

Adoption of legislation for joint EU HTA Assessment has initiated a new era, with the Joint Clinical Assessment (JCA) being implemented for cancer and Advanced Therapy Medicinal Products (ATMPs) from January 2025. Our MD Anand Jha is moderating a session on this topic on 7th October, 2024 at the Pharma Marcon conference in Berlin, with fellow panelists Sandeep Kiri Stephanie Dr. med. Rosenfeld Inka Heikkinen Thomas Grub to look at the challenges that the companies will face for access planning and how to address them. The discussion will cover multiple aspects that the industry and multiple stakeholder groups are grappling with... Anastasia Trubnikova #euhta #healthpolicy #patientaccess #eunethta

Attended Everylife's insightful workshop yesterday discussing ultra-rare diseases and therapies. I look forward to the workshop report!